- Home
- BRT vs SABS Comparison
BRT vs SABS Comparison
Compare BRT & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | SABS |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | 86 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 298.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRT | SABS |
|---|---|---|
| Price | $14.74 | $3.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $19.75 | $10.75 |
| AVG Volume (30 Days) | 45.3K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $1.77 |
| 52 Week High | $16.69 | $6.60 |
Technical Indicators
Market Signals| Indicator | BRT | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 56.87 |
| Support Level | $14.25 | $3.48 |
| Resistance Level | $15.01 | $4.10 |
| Average True Range (ATR) | 0.39 | 0.26 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 22.37 | 68.79 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.